
Opinion|Videos|July 17, 2024
Considerations for Managing PNH Treatment Complications
Medical experts navigate significant challenges associated with PNH treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the key considerations and best practices for monitoring patients with PNH over time, particularly in assessing treatment effectiveness and managing potential complications like cytopenia and thrombotic risks?
Advertisement
Related to this article

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
Health Equity & Access Weekly Roundup: November 6, 2026
4
GLP-1 RAs Improve MASLD, MASH Markers, but Long-Term Benefits Unclear
5

